Ascendis Pharma Says US FDA Extends Review Period on Hypoparathyroidism Treatment; Shares Drop-March 2024-www.financetom.com

Ascendis Pharma Says US FDA Extends Review Period on Hypoparathyroidism Treatment; Shares Drop

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Ascendis Pharma Says US FDA Extends Review Period on Hypoparathyroidism Treatment; Shares Drop

May 14, 2024 12:43 PM

03:20 PM EDT, 05/14/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) said Tuesday the US Food and Drug Administration postponed its decision on the company's new drug application for TransCon PTH, or palopegteriparatide, for adults with hypoparathyroidism,

The regulator plans to make a decision by Aug. 14, three months later than the previous target date, after the company submitted additional information for the review that constituted a major amendment to the application, according to a statement.

Ascendis Pharma ( ASND ) shares fell 6.7% in recent Tuesday trading.

Price: 123.19, Change: -8.83, Percent Change: -6.69

Previous page： eXp World Names Jesse Hill as Interim Finance Chief Next page： Asana Insider Bought Shares Worth $9,157,500, According to a Recent SEC Filing

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

eXp World Names Jesse Hill as Interim Finance Chief

Mar 18, 2025

03:28 AM EDT, 03/18/2025 (MT Newswires) -- eXp World Holdings ( EXPI ) said late Monday it has appointed Jesse Hill as interim chief financial officer, effective April 1. Hill, who currently serves as vice president, will succeed current principal financial officer Kent Cheng, who will serve in an advisory capacity beginning March 31 until Aug. 31. The company said...

Asana Insider Bought Shares Worth $9,157,500, According to a Recent SEC Filing

Mar 18, 2025

03:24 AM EDT, 03/18/2025 (MT Newswires) -- Dustin A. Moskovitz, 10% Owner, Director, President, Chief Executive Officer & Chair, on March 13, 2025, executed a purchase for 675,000 shares in Asana (ASAN) for $9,157,500. Following the Form 4 filing with the SEC, Moskovitz has control over a total of 52,720,482 Class A common shares of the company, with 48,573,436 shares...

Lazard Insider Sold Shares Worth $5,859,927, According to a Recent SEC Filing

Mar 18, 2025

03:23 AM EDT, 03/18/2025 (MT Newswires) -- Peter Richard Orszag, Director, Chief Executive Officer & Chairman, on March 13, 2025, sold 129,078 shares in Lazard ( LAZ ) for $5,859,927. Following the Form 4 filing with the SEC, Orszag has control over a total of 170,285 common shares of the company, with 170,285 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1311370/000162828025013284/xslF345X05/wk-form4_1742251374.xml ...

Equitable Holdings Insider Sold Shares Worth $1,534,767, According to a Recent SEC Filing

Mar 18, 2025

03:19 AM EDT, 03/18/2025 (MT Newswires) -- Mark Pearson, Director, President and Chief Executive Officer, on March 14, 2025, sold 30,000 shares in Equitable Holdings ( EQH ) for $1,534,767. Following the Form 4 filing with the SEC, Pearson has control over a total of 753,206 common shares of the company, with 753,206 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1333986/000162828025013288/xslF345X05/wk-form4_1742251630.xml ...